drugset / Trial / NCT01683695

Safety Study of AMG 557 in Subjects With Lupus Arthritis

NCT01683695 ↗

Phase 1 Completed 20 enrolled Amgen
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a multicenter, randomized, double-blind, parallel, placebo-controlled, multiple dose study that will enroll approximately 40 systemic lupus erythematosus subjects with active lupus arthritis.

Timeline

Start
2012-06
Primary completion
2016-03
Completion
2016-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator AMG 557 Monoclonal antibody 210 mg Subcutaneous